摘要
目前诊断人类疾病的方法仍然无法以可承受的价格快速、准确地同时大规模筛查多种疾病。 MALDI-ToF 质谱是一种超灵敏、超快速、低成本、高通量技术,有可能实现这一目标,允许人类表型表征,从而对多种疾病状态进行表型筛选。在这篇综述中,我们将讨论迄今为止取得的主要进展,提出 MALDI-ToF 质谱在人类疾病检测服务中的有针对性的应用。本综述侧重于使用最先进的生物信息学管道和软件工具进行表型分析的 MALDI-ToF 数据处理方法学工作流程。考虑了数学建模、机器学习和人工智能算法在疾病筛查中的作用。此外,我们提出了一些先前开发的基于 MALDI-ToF 分析的疾病诊断和筛查工具。我们讨论了在临床实验室中实施 MALDI-ToF 时面临的剩余挑战。从单一疾病表型中区分标准概况是具有挑战性的,但是一旦克服了这个初始障碍,同时运行针对不同疾病表型的多个算法筛选的潜力可能只会受到计算能力的限制。探索人类临床表型组学的全部潜力的能力可能比想象的更近;这篇综述深入了解了这项技术可能为临床诊断的未来带来的好处。
关键词: 质谱、MALDI ToF、表型组学、机器学习、生物信息学、预测建模。
Current Medicinal Chemistry
Title:MALDI-ToF Mass Spectra Phenomic Analysis for Human Disease Diagnosis Enabled by Cutting-Edge Data Processing Pipelines and Bioinformatics Tools
Volume: 28 Issue: 32
关键词: 质谱、MALDI ToF、表型组学、机器学习、生物信息学、预测建模。
摘要: Current methods for diagnosing human disease are still incapable of rapidly and accurately screening for multiple diseases simultaneously on a large scale, and at an affordable price. MALDI-ToF mass spectrometry is an ultra-sensitive, ultra-fast, lowcost, high-throughput technology that has the potential to achieve this goal, allowing human phenotype characterization and thus phenomic screening for multiple disease states. In this review, we will discuss the main advances achieved so far, putting forward targeted applications of MALDI-ToF mass spectrometry in the service of human disease detection. This review focuses on the methodological workflow as MALDI-ToF data processing for phenomic analysis, using state-of-the-art bioinformatic pipelines and software tools. The role of mathematical modelling, machine learning, and artificial intelligence algorithms for disease screening are considered. Moreover, we present some previously developed tools for disease diagnostics and screening based on MALDI-ToF analysis. We discuss the remaining challenges that are ahead when implementing MALDI-ToF into clinical laboratories. Differentiating a standard profile from a single disease phenotype is challenging, but the potential to simultaneously run multiple algorithm screens for different disease phenotypes may only be limited by computing power once this initial hurdle is overcome. The ability to explore the full potential of human clinical phenomics may be closer than imagined; this review gives an insight into the benefits this technology may reap for the future of clinical diagnostics.
Export Options
About this article
Cite this article as:
MALDI-ToF Mass Spectra Phenomic Analysis for Human Disease Diagnosis Enabled by Cutting-Edge Data Processing Pipelines and Bioinformatics Tools, Current Medicinal Chemistry 2021; 28 (32) . https://dx.doi.org/10.2174/0929867327666201027154257
DOI https://dx.doi.org/10.2174/0929867327666201027154257 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Could Growth Factor-Mediated Extracellular Matrix Deposition and Degradation Offer the Ground for Directed Pharmacological Targeting in Fibrosarcoma?
Current Medicinal Chemistry Treatment of Mild Cognitive Impairment (MCI)
Current Alzheimer Research Critical Issues for Successful Immunotherapy in Alzheimers Disease: Development of Biomarkers and Methods for Early Detection and Intervention
CNS & Neurological Disorders - Drug Targets Prognostic Role of Ovarian Reserve Testing
Current Women`s Health Reviews Methylene Blue and Vasoplegia: Who, When, and How?
Mini-Reviews in Medicinal Chemistry MicroRNA Dysregulation in the Myelodysplastic Syndromes
MicroRNA Clinical, Genetic, and Neuroimaging Features of Early Onset Alzheimer Disease: The Challenges of Diagnosis and Treatment
Current Alzheimer Research Oncogenic Signaling in Acute Myeloid Leukemia
Current Drug Targets Role of Trisomy 21 Mosaicism in Sporadic and Familial Alzheimer’s Disease
Current Alzheimer Research Neonatology in the United States: Where we are, and where we are Going
Current Pediatric Reviews New Anti-Angiogenic Targeted Therapy in Advanced Renal Cell Carcinoma (RCC):Current Status and Future Prospects
Reviews on Recent Clinical Trials Navigating the Sea Changes in Patent Law to Successfully Build Value
Technology Transfer and Entrepreneurship (Discontinued) The Combination of Conventional Chemotherapy with New Targeted Therapy in Hematologic Malignancies: The Safety and Efficiency of Low- Dose Cytarabine Supports its Combination with New Therapeutic Agents in Early Clinical Trials
Current Cancer Therapy Reviews Biological Basis of Novel Therapies for Myelodysplastic Syndrome
Current Cancer Therapy Reviews Role of Genetic Factors in the Pathogenesis of Radial Deficiencies in Humans
Current Genomics Influence of Mutations in the Hepatitis B Virus Genome on Virus Replication and Drug Resistance - Implications for Novel Antiviral Strategies
Current Medicinal Chemistry Involvement of MAPK Signalling in Human Villous Trophoblast Differentiation
Mini-Reviews in Medicinal Chemistry Insights from Mouse Models to Understand Neurodegeneration in Down Syndrome
CNS & Neurological Disorders - Drug Targets Rationale for the Development of Cholinesterase Inhibitors as Anti- Alzheimer Agents
Current Pharmaceutical Design Gene Clusters, Molecular Evolution and Disease: A Speculation
Current Genomics